Urinalysis Market Report 2025

The urinalysis market size has grown strongly in recent years. It will grow from $3.57 billion in 2024 to $3.83 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising healthcare expenditure, healthcare infrastructure, regulatory changes and standardization, drug screening and forensics, clinical laboratory practices.

The urinalysis market size is expected to see strong growth in the next few years. It will grow to $5.47 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to point-of-care testing (POCT), chronic disease management, aging population, preventive healthcare, remote monitoring and telemedicine. Major trends in the forecast period include innovative drugs approvals, technological innovations, personalized medicine, chronic disease monitoring.

The urinalysis market is anticipated to witness growth due to the rising geriatric population. The geriatric population, comprising individuals aged 65 and beyond, often experiences various diseases due to lower immunity and the effects of aging. Among the health concerns in this demographic, the increased risk of urinary tract infections (UTI) is notable. Urinalysis, which examines the visual, chemical, and microscopic components of urine, plays a crucial role in identifying and managing various illnesses prevalent in the geriatric population, including diabetes, kidney disease, and urogenital infections. According to the World Health Organization, by 2030, six people in the world will be aged 60 or older, reaching 1.4 billion individuals. The global population aged 60 and older is expected to double to 2.1 billion by 2050. The escalating number of elderly individuals, particularly those aged 80 and older, underscores the significance of urinalysis in addressing the healthcare needs of the geriatric population and, consequently, driving the urinalysis market.

The increasing incidence of chronic kidney disease is anticipated to drive the growth of the urinalysis market in the future. Chronic kidney disease is characterized by the kidneys' diminished ability to filter blood effectively due to gradual damage and loss of function. Urinalysis plays a crucial role in diagnosing, monitoring, and managing chronic kidney disease (CKD), offering valuable insights into kidney health and overall bodily function. For example, in June 2023, publications by the Oxford University Press, a UK-based department of the University of Oxford, projected that the prevalence of chronic kidney disease (CKD) in the UK would rise by 4%, increasing from 8.27 million to 8.61 million individuals between 2022 and 2032. Therefore, the rising prevalence of chronic kidney disease is fueling the growth of the urinalysis market.

Technologically advanced instruments, incorporating artificial intelligence (AI) technology in urine analysis devices, represent a key trend gaining popularity in the urinalysis market. Notably, Olive Diagnostics, an Israel-based health tech company, launched Olive KG in February 2022. This urinalysis sensor device, powered by AI, provides real-time health alerts and early detection of disease progression. Olive KG measures various parameters, including red blood cells, proteins, ketones, nitrites, pH, volume, pressure, color, and urine frequency. Designed as a toilet-mountable Internet of Medical Things (IoMT) device, Olive KG delivers real-time personal data while adhering to GDPR and HIPPA act criteria. The integration of AI technology in urinalysis instruments exemplifies a technological advancement that enhances the efficiency and capabilities of urine analysis, contributing to the market's growth.

Major players in the urinalysis market are actively engaged in developing innovative products, such as urine particle analyzers, to secure a competitive advantage. Urine analyzers are clinical devices designed for automated urine testing, offering capabilities for the detection and quantification of multiple analytes. Urine particle analyzers, in particular, provide enhanced accuracy and precision compared to manual microscopy, contributing to the standardization of urine particle analysis and reducing inter-observer variability. A notable example of this trend is Sysmex Europe SE, a Germany-based automated in vitro diagnostics provider, which introduced the UF-1500 Fully Automated Urine Particle Analyzer in April 2023. This innovative device is engineered to achieve a significant reduction in footprint (approximately 30%) while maintaining high levels of performance and usability. Leveraging cutting-edge fluorescence flow cytometry technology, similar to Sysmex's flagship UF-5000, the UF-1500 caters to diverse customer needs. It serves as a fully automated urinalysis workstation for both developed and emerging markets, as well as backup and satellite systems for extensive facilities that have previously installed the UN-Series. Additionally, the UF-1500 supports connectivity to Sysmex's UC-3500 urine chemistry analyzers.

In June 2022, Healthy.io Ltd., a US-based healthcare company specializing in remote clinical testing and services, acquired Inui Health for $9 million. This acquisition enabled Healthy.io Ltd. to acquire smartphone diagnostics platforms and various at-home testing services, which will enhance the company's growth in the smartphone diagnostic market. Inui Health is a US-based medical diagnostics company that offers consumers the ability to perform urinalysis at home using their smartphones.

Major companies operating in the urinalysis market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd., Cardinal Health Inc., Abbott Laboratories, Danaher Corporation, Beckman Coulter Inc., Sysmex Corporation, ARKRAY Inc., ACON Laboratories Inc., Bio-Rad Laboratories Inc., URIT Medical Electronic Group Co Ltd., 77 Elektronika Kft, Thermo Fisher Scientific Inc., Teco Diagnostics, Mindray Medical International Limited, Quidel Corporation, Becton Dickinson and Company, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Guangzhou Wondfo Biotech Co. Ltd., Chembio Diagnostic Systems Inc, Immunostics Inc., Inova Diagnostics Inc., Meridian Bioscience Inc., Fapon Biotech Inc., Nanjing Norman Biological Technology Co. Ltd., OraSure Technologies Inc., Hologic Inc., Randox Laboratories Ltd., Qiagen N.V.

North America was the largest region in the urinalysis market in 2024. The regions covered in the urinalysis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinalysis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A urinalysis, commonly known as a urine test, is a diagnostic examination that assesses the visual, chemical, and microscopic elements present in urine. It evaluates the appearance, concentration, and content of urine, encompassing various tests to detect and measure compounds that are excreted in urine through a single sample. This diagnostic tool is employed to identify and manage a range of health conditions, including diabetes, kidney disease, and urogenital infections.

The primary test types within urinalysis include pregnancy and fertility tests, biochemical urinalysis, and sediment urinalysis. Pregnancy and fertility tests specifically focus on detecting a hormone, human chorionic gonadotropin (HCG), in blood or urine to confirm pregnancy or aid couples in family planning decisions. Regardless of pregnancy intentions, these tests assist in determining pregnancy status. Products used in urinalysis procedures consist of consumables and instruments, applied in diagnosing conditions such as urinary tract infections (UTIs), kidney disease, liver disease, diabetes, hypertension, among others. Urinalysis is utilized across various settings including diagnostic laboratories, hospitals, clinics, home care settings, as well as research laboratories and institutes.

The urinalysis market research report is one of a series of new reports that provides urinalysis market statistics, including urinalysis industry global market size, regional shares, competitors with a urinalysis market share, detailed urinalysis market segments, market trends and opportunities, and any further data you may need to thrive in the urinalysis industry. This urinalysis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinalysis market consists of revenues earned by entities by providing urinalysis services by providing visual exam of urine, dipstick test, screening tests, reagents test, culture test and microscopic exam of urine. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinalysis market also includes sales of automated urine analyzers, point of care analyzers, integrated urine analyzers, strip reader connect system equipment which are used in providing urinalysis services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.